Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
210M
-
Number of holders
-
150
-
Total 13F shares, excl. options
-
128M
-
Shares change
-
-5.71M
-
Total reported value, excl. options
-
$438M
-
Value change
-
-$23.5M
-
Put/Call ratio
-
1.23
-
Number of buys
-
83
-
Number of sells
-
-77
-
Price
-
$3.44
Significant Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) as of Q3 2020
201 filings reported holding BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share as of Q3 2020.
BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) has 150 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 128M shares
of 210M outstanding shares and own 60.83% of the company stock.
Largest 10 shareholders include STATE STREET CORP (16.2M shares), BlackRock Inc. (15.9M shares), BAKER BROS. ADVISORS LP (12.7M shares), VANGUARD GROUP INC (11.5M shares), CITADEL ADVISORS LLC (8.66M shares), Sarissa Capital Management LP (4.86M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (4.46M shares), MILLENNIUM MANAGEMENT LLC (3.39M shares), ORACLE INVESTMENT MANAGEMENT INC (2.53M shares), and GEODE CAPITAL MANAGEMENT, LLC (2.44M shares).
This table shows the top 150 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.